Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology.

Clindamycin is a lincosamide antibiotic that has been used as a topical, oral, or injectable formulation for over five decades. It exhibits a narrow spectrum of microbiologic activity, primarily against gram-positive and anaerobic bacteria. In dermatology, clindamycin has been used primarily as a topical agent, usually for the treatment of acne vulgaris. Despite questions surrounding antibiotic resistance and/or its relative contribution to antibiotic treatment efficacy, a large body of data support the therapeutic value of topical clindamycin for acne vulgaris. As a systemic agent, clindamycin is used orally to treat a variety of cutaneous bacterial infections, and sometimes for acne vulgaris, with oral treatment for the latter less common in more recent years. The modes of action of clindamycin are supported by data showing both its anti-inflammatory and antibiotic mechanisms, which are discussed here along with pharmacokinetic profiles and structure-activity relationships. The diverse applications of clindamycin for multiple disease states, its efficacy, and safety considerations are also reviewed here, including for both topical and systemic formulations. Emphasis is placed on uses in dermatology, but other information on clindamycin relevant to clinicians is also discussed.

Informations de copyright

Copyright © 2024. Matrix Medical Communications. All rights reserved.

Déclaration de conflit d'intérêts

DISCLOSURES: Dr. Del Rosso is a researcher, consultant, and/or speaker for Almirall, Bausch Health (Ortho Dermatologics), Galderma, Journey, Mayne Pharma, SolGel, Sun Pharma, and Vyne. He is also the current president of the American Acne and Rosacea Society. Dr. Grada was previously an employee of Almirall prior to the development of this manuscript.